Description
Verucerfont is a corticotropin-releasing factor receptor 1 ( CRF1 ) antagonist with IC 50 s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.In VivoPost hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316 311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailed Post hoc analysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6 h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline). MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:IC50: 6.1 nM (CRF1), >1000 nM (CRF2), >1000 nM (CRF-BP)